Known targets — ChEMBL curated mechanism
PDE10APDE3APDE4APDE4BPDE4CPDE4DPDE5A
The experimentally established mechanism targets of Ibudilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 7/20 | 0.87 |
| ▸ | PDE5A known ✓ | O76074 | 6/20 | 0.87 |
| ▸ | PDE3A known ✓ | Q14432 | 4/20 | 0.87 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.87 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.87 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.87 |
| ▸ | MIF | P14174 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.87 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibudilast SCHEMBL4194864 | 0.93 | PDE4B (1.00) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Ibudilast SCHEMBL30390 | 0.93 | PDE4B (1.00) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Ibudilast SCHEMBL1123689 | 0.91 | PDE4B (0.94) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Ibudilast SCHEMBL1123688 | 0.91 | PDE4B (0.94) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL14863727 | 0.87 | PDE4B (0.73) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL8224246 | 0.84 | PDE4B (0.77) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL3203334 | 0.83 | PDE4B (0.81) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Hydrochloric Acid SCHEMBL3199551 | 0.83 | PDE4B (0.75) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL10033623 | 0.82 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL653193 | 0.82 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689390-B1 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ZALICUS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100210606-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ZALICUS INC. | 2010-08-19 | — | — | US | disclosed |
| US-7709495-B2 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1689390-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1689390-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050187203-A1 | combination of a pyrazolo(1,5-a)pyridine compound such as ibudilast with a corticosteroid; treating immunoinflammatory disorders e.g. rheumatoid arthritis, ulcerative colitis | ZALICUS INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005051293-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187203-A1 | combination of a pyrazolo(1,5-a)pyridine compound such as ibudilast with a corticosteroid; treating immunoinflammatory disorders e.g. rheumatoid arthritis, ulcerative colitis | PTGER4, IL4, P2RY4 | PDE4B 152/4885PDE5A 229/4885PDE3A 362/4885 |
| US-20100210606-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL4, PTGER4, TSLP | PDE4B 421/4885PDE5A 1148/4885PDE3A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.